Trials / Unknown
UnknownNCT05313906
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
Disitamab Vedotin Plus Penpulimab and Cisplatin in Advanced Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.
Detailed description
Although anti-PD-1 antibody could prolong the survival of patients with adanced gastic cancer, there are relatively few reports on anti-PD-1 antibody therapy in Her2-positive gastric cancer. RC48 is a primary anti-HER2 antibody-drug conjugate, which has been approved by the Chinese NMPA for the later-line treatment of Her2-positive gastric cancer. This study was to explore the safety and clinical efficacy of RC48 combined with cisplatin and AK105 in previously untreated patients with HER2-positive gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC48+AK105+cisplatin | RC48 plus AK105 and cisplatin |
Timeline
- Start date
- 2022-05-07
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
- First posted
- 2022-04-06
- Last updated
- 2022-04-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05313906. Inclusion in this directory is not an endorsement.